Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain.
Animal studies suggest differential effects of cannabinoids on dopamine-related behaviours in adolescence and adulthood however few studies have investigated the underlying neurochemical effects of cannabinoids during adolescence. The aim of the present study was to compare the effects of treatment with the synthetic cannabinoid, HU210, on dopamine receptor density in adolescent and adult rats. Adolescent (postnatal day (PND) 35) and adult (PND 70) rats received a single dose of 100μg/kg HU210 or 25, 50 or 100μg/kg HU210 for 4 or 14 days. Dopamine D1 receptor (D1R) or D2 receptor (D2R) density was measured in the medial and lateral (CPUL) caudate putamen, nucleus accumbens, olfactory tubercle (TU) and substantia nigra (D1R only) using in vitro autoradiography. D1R and D2R densities were 1.6-1.7- and 1.1-1.4-fold higher respectively in adolescent control rats compared to adults. In adult rats, D1R density was increased by 1.2- and 1.3-fold (p<0.05) in CPUL and TU respectively compared to controls, after 14 days of HU210 treatment. A significant overall effect of treatment (p<0.05) on D2R density was also observed in adults after the single dose and 4 and 14 days administration of HU210. In adolescents, an overall effect of treatment on D1R density after a single exposure to HU210 was seen (p=0.0026) but no changes in D1R or D2R densities were observed in other treatment groups. These results suggest that the adolescent rat brain does not display the same compensatory mechanisms activated in the adult brain following cannabinoid treatment.
Dalton
Victoria S
VS
Schizophrenia Research Institute, Sydney, Australia. victoria.dalton@ansto.gov.au
Zavitsanou
Katerina
K
D000375:Aging / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D029681:Arabidopsis Proteins / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D014157:Transcription Factors / Q000187:drug effects / Q000502:physiology
D029681:Arabidopsis Proteins; C556504:DDA1 protein, Arabidopsis; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D014157:Transcription Factors; D013759:Dronabinol; C062018:HU 211; D004298:Dopamine